About Express Scripts Holding Company (NASDAQ:ESRX)
Express Scripts, Inc. is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM). PBM segment’s services include retail network pharmacy management and retail drug card programs, home delivery services, specialty benefit services, patient care contact centers, benefit plan design and consultation, drug formulary management, compliance and therapy management programs, information reporting and analysis programs, rebate programs, and electronic claims processing and drug utilization review. EM segment’s services include distribution of pharmaceuticals and medical supplies to providers and clinics and healthcare account administration and implementation of consumer-directed healthcare solutions.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Health Care Plans
- Sub-Industry: Health Care Services
- Symbol: NASDAQ:ESRX
- CUSIP: 30219G10
- Web: www.express-scripts.com
Capitalization:- Market Cap: $32.81056 billion
- Outstanding Shares: 577,549,000
Average Prices:- 50 Day Moving Avg: $61.90
- 200 Day Moving Avg: $62.41
- 52 Week Range: $56.62 - $77.50
P/E:- Trailing P/E Ratio: 9.93
- Foreward P/E Ratio: 7.48
- P/E Growth: 0.67
Sales & Book Value:- Annual Revenue: $100.28 billion
- Price / Sales: 0.33
- Book Value: $27.26 per share
- Price / Book: 2.10
Profitability:- EBITDA: $7.16 billion
- Net Margins: 3.50%
- Return on Equity: 25.58%
- Return on Assets: 7.96%
Debt:- Debt-to-Equity Ratio: 0.88%
- Current Ratio: 0.69%
- Quick Ratio: 0.58%
Misc:- Average Volume: 3.25 million shs.
- Beta: 0.88
- Short Ratio: 9.82
Frequently Asked Questions for Express Scripts Holding Company (NASDAQ:ESRX)
What is Express Scripts Holding Company's stock symbol?
Express Scripts Holding Company trades on the NASDAQ under the ticker symbol "ESRX."
How were Express Scripts Holding Company's earnings last quarter?
Express Scripts Holding Company (NASDAQ:ESRX) issued its quarterly earnings data on Tuesday, July, 25th. The company reported $1.73 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.71 by $0.02. The business had revenue of $25.35 billion for the quarter, compared to the consensus estimate of $25.52 billion. Express Scripts Holding Company had a net margin of 3.50% and a return on equity of 25.58%. The company's quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.57 EPS. View Express Scripts Holding Company's Earnings History.
When will Express Scripts Holding Company make its next earnings announcement?
What guidance has Express Scripts Holding Company issued on next quarter's earnings?
Express Scripts Holding Company updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of $6.95-7.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.97. Express Scripts Holding Company also updated its Q3 guidance to $1.88-1.92 EPS.
Where is Express Scripts Holding Company's stock going? Where will Express Scripts Holding Company's stock price be in 2017?
20 analysts have issued 12-month target prices for Express Scripts Holding Company's shares. Their predictions range from $56.00 to $85.00. On average, they anticipate Express Scripts Holding Company's share price to reach $68.50 in the next twelve months. View Analyst Ratings for Express Scripts Holding Company.
What are analysts saying about Express Scripts Holding Company stock?
Here are some recent quotes from research analysts about Express Scripts Holding Company stock:
- 1. According to Zacks Investment Research, "We are upbeat about Express Scripts’ pharmacy-benefits management long-term outlook. The projection takes the volatile healthcare market trends, inflation, patent expiration and lower industry utilization growth into consideration. Furthermore, Express Scripts should benefit from increased generic utilization, shift toward mail orders, strong specialty growth and an aging population. Branded drugs are becoming increasingly expensive due to double-digit brand inflation. Thus, continued rise in the price of specialty drugs and overwhelming regulatory burden is opening up considerable prospects for generics. However, over the past one year, Express Scripts has underperformed the broader industry in terms of price. Tough competition in the niche space and the persistent drug pricing issue are anticipated to affect the stock." (10/16/2017)
- 2. Jefferies Group LLC analysts commented, "We believe ESRX remains a Buy given our view that company fundamentals, including its FCF, are stable and that the stock's valuation is attractive at 9x FY18 P/E. That said, we recognize that headlines surrounding drug pricing pressure and the overhang from ESRX's Anthem contract will drive continued stock volatility NT." (2/17/2017)
Are investors shorting Express Scripts Holding Company?
Express Scripts Holding Company saw a increase in short interest during the month of September. As of September 29th, there was short interest totalling 32,966,022 shares, an increase of 3.9% from the September 15th total of 34,319,116 shares. Based on an average daily volume of 3,654,812 shares, the days-to-cover ratio is currently 9.0 days. Currently, 5.7% of the company's stock are short sold.
Who are some of Express Scripts Holding Company's key competitors?
Some companies that are related to Express Scripts Holding Company include Stryker Corporation (SYK), Aetna (AET), Anthem (ANTM), Regeneron Pharmaceuticals (REGN), Becton, Dickinson and Company (BDX), Takeda Pharmaceutical (TKPYY), Boston Scientific Corporation (BSX), Intuitive Surgical (ISRG), Vertex Pharmaceuticals Incorporated (VRTX), Baxter International (BAX), Humana (HUM), Zoetis (ZTS), Alexion Pharmaceuticals (ALXN), McKesson Corporation (MCK), Illumina (ILMN), Actelion (ALIOF), Fresenius Medical Care Corporation (FMS) and HCA Holdings (HCA).
Who owns Express Scripts Holding Company stock?
Express Scripts Holding Company's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bridges Investment Management Inc. (0.01%), Eqis Capital Management Inc. (0.00%), First National Bank of Mount Dora Trust Investment Services (0.00%), Beacon Financial Group (0.00%), Osborn Williams & Donohoe LLC (0.00%) and Bridges Investment Counsel Inc. (0.00%). Company insiders that own Express Scripts Holding Company stock include Christopher A Mcginnis, Everett Neville, Mahon Thomas P Mac, Phyllis S Anderson and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts Holding Company.
Who sold Express Scripts Holding Company stock? Who is selling Express Scripts Holding Company stock?
Express Scripts Holding Company's stock was sold by a variety of institutional investors in the last quarter, including Bridges Investment Counsel Inc., First National Bank of Mount Dora Trust Investment Services and Bridges Investment Management Inc.. Company insiders that have sold Express Scripts Holding Company stock in the last year include Everett Neville, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts Holding Company.
Who bought Express Scripts Holding Company stock? Who is buying Express Scripts Holding Company stock?
How do I buy Express Scripts Holding Company stock?
Shares of Express Scripts Holding Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Express Scripts Holding Company's stock price today?
One share of Express Scripts Holding Company stock can currently be purchased for approximately $57.21.
MarketBeat Community Rating for Express Scripts Holding Company (NASDAQ ESRX)MarketBeat's community ratings are surveys of what our community members think about Express Scripts Holding Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Express Scripts Holding Company (NASDAQ:ESRX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Sell Ratings, 11 Hold Ratings, 5 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.05) |
| Consensus Price Target: | $68.50 (19.73% upside) |
Consensus Price Target History for Express Scripts Holding Company (NASDAQ:ESRX)
Analysts' Ratings History for Express Scripts Holding Company (NASDAQ:ESRX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/9/2017 | Raymond James Financial, Inc. | Reiterated Rating | Market Perform -> Underperform | | N/A |  |
| 9/19/2017 | Royal Bank Of Canada | Initiated Coverage | Sector Perform -> Sector Perform | $68.00 | High | |
| 9/1/2017 | Robert W. Baird | Reiterated Rating | Hold | $56.00 | Medium | |
| 8/29/2017 | Jefferies Group LLC | Set Price Target | Buy | $72.00 | Low | |
| 8/10/2017 | Morgan Stanley | Boost Price Target | Underweight | $52.00 -> $57.00 | Low | |
| 7/21/2017 | Needham & Company LLC | Initiated Coverage | Hold -> Hold | | Low | |
| 6/9/2017 | Cowen and Company | Reiterated Rating | Outperform | $83.00 | Low | |
| 4/26/2017 | Evercore ISI | Lower Price Target | In-Line | $68.50 -> $59.00 | Medium | |
| 4/26/2017 | Edward Jones | Downgrade | Buy -> Hold | | High | |
| 4/25/2017 | SunTrust Banks, Inc. | Reiterated Rating | Buy | | High | |
| 4/25/2017 | Bank of America Corporation | Reiterated Rating | Neutral | $77.00 | High | |
| 4/25/2017 | Mizuho | Lower Price Target | Neutral -> Neutral | $76.00 -> $61.00 | High | |
| 3/29/2017 | Argus | Reiterated Rating | Hold | | Low | |
| 3/15/2017 | Wells Fargo & Company | Downgrade | Market Perform -> Underperform | | Low | |
| 3/8/2017 | Leerink Swann | Reiterated Rating | Market Perform | $75.00 | Low | |
| 2/16/2017 | Credit Suisse Group | Reiterated Rating | Buy | $85.00 | N/A | |
| 2/14/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Hold | | N/A | |
| 12/16/2016 | Barclays PLC | Reiterated Rating | Overweight | | N/A | |
| 12/1/2016 | Sanford C. Bernstein | Reiterated Rating | Underperform | $59.00 | N/A | |
| 11/3/2016 | Deutsche Bank AG | Upgrade | Sell -> Hold | $69.00 -> $70.00 | N/A | |
| 6/1/2016 | Wedbush | Reiterated Rating | Neutral | | N/A | |
| 5/24/2016 | Citigroup Inc. | Reiterated Rating | Buy | | N/A | |
| 4/27/2016 | FBR & Co | Lower Price Target | Mkt Perform | $90.00 -> $75.00 | N/A | |
| 3/18/2016 | William Blair | Reiterated Rating | Buy | | N/A | |
| 2/18/2016 | Goldman Sachs Group, Inc. (The) | Lower Price Target | Neutral | $82.00 -> $74.00 | N/A | |
| 2/17/2016 | Maxim Group | Reiterated Rating | Buy | $109.00 -> $95.00 | N/A | |
| 12/23/2015 | BMO Capital Markets | Boost Price Target | Market Perform | $94.00 | N/A | |
| 11/29/2015 | J P Morgan Chase & Co | Reiterated Rating | Buy | $105.00 | N/A | |
(Data available from 10/18/2015 forward)
Earnings History for Express Scripts Holding Company (NASDAQ:ESRX)Earnings History by Quarter for Express Scripts Holding Company (NASDAQ ESRX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/24/2017 | | $1.89 | | | | | N/A | |
| 7/25/2017 | Q2 2017 | $1.71 | $1.73 | $25.52 billion | $25.35 billion | View | N/A | |
| 4/24/2017 | Q1 17 | $1.32 | $1.33 | $24.95 billion | $24.65 billion | View | N/A | |
| 2/14/2017 | Q4 2016 | $1.87 | $1.88 | $26.31 billion | $24.90 billion | View | Listen | |
| 10/25/2016 | Q3 | $1.74 | $1.74 | $25.48 billion | $25.41 billion | View | Listen | |
| 7/25/2016 | Q216 | $1.57 | $1.57 | $25.42 billion | $25.20 billion | View | Listen | |
| 4/25/2016 | Q1 | $1.22 | $1.22 | $25.20 billion | $24.80 billion | View | Listen | |
| 2/16/2016 | Q4 | $1.56 | $1.56 | $26.58 billion | $26.18 billion | View | Listen | |
| 10/27/2015 | Q315 | $1.44 | $1.45 | $26.38 million | $25.22 million | View | Listen | |
| 7/28/2015 | Q215 | $1.40 | $1.44 | $26.13 billion | $25.45 billion | View | Listen | |
| 4/28/2015 | Q115 | $1.10 | $1.10 | $24.34 billion | $24.90 billion | View | Listen | |
| 2/23/2015 | Q414 | $1.38 | $1.39 | $25.68 billion | $26.31 billion | View | Listen | |
| 10/28/2014 | Q314 | $1.29 | $1.29 | $24.93 billion | $25.78 billion | View | Listen | |
| 7/29/2014 | Q214 | $1.22 | $1.23 | $24.42 billion | $25.11 billion | View | Listen | |
| 4/29/2014 | Q114 | $1.01 | $0.99 | $23.81 billion | $23.69 billion | View | Listen | |
| 2/20/2014 | Q413 | $1.12 | $1.12 | $25.49 billion | $25.78 billion | View | N/A | |
| 10/25/2013 | Q313 | $1.08 | $1.08 | $25.01 billion | $25.92 billion | View | Listen | |
| 7/29/2013 | Q2 2013 | $1.10 | $1.12 | $25.51 billion | $26.40 billion | View | Listen | |
| 4/29/2013 | Q1 2013 | $0.97 | $0.99 | $25.55 billion | $26.06 billion | View | Listen | |
| 2/18/2013 | Q4 2012 | $1.04 | $1.05 | $27.24 billion | $27.41 billion | View | Listen | |
| 11/5/2012 | Q312 | $0.99 | $1.02 | $27.48 billion | $27.00 billion | View | N/A | |
| 8/7/2012 | | $0.82 | $0.88 | | | View | N/A | |
| 5/10/2012 | | $0.77 | $0.73 | | | View | N/A | |
| 2/22/2012 | | $0.85 | $0.82 | | | View | N/A | |
| 10/25/2011 | | $0.77 | $0.79 | | | View | N/A | |
| 7/21/2011 | | $0.69 | $0.71 | | | View | N/A | |
| 4/26/2011 | | $0.69 | $0.66 | | | View | N/A | |
| 2/16/2011 | | $0.70 | $0.71 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Express Scripts Holding Company (NASDAQ:ESRX)2017 EPS Consensus Estimate: $6.98
2018 EPS Consensus Estimate: $7.63
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | $1.31 | $1.33 | $1.32 |
| Q2 2017 | 5 | $1.68 | $1.72 | $1.70 |
| Q3 2017 | 5 | $1.90 | $1.91 | $1.90 |
| Q4 2017 | 5 | $2.03 | $2.07 | $2.05 |
| Q1 2018 | 4 | $1.45 | $1.52 | $1.49 |
| Q2 2018 | 4 | $1.85 | $1.92 | $1.88 |
| Q3 2018 | 4 | $2.02 | $2.09 | $2.05 |
| Q4 2018 | 4 | $2.16 | $2.26 | $2.21 |
| Q1 2019 | 1 | $1.59 | $1.59 | $1.59 |
| Q2 2019 | 1 | $2.01 | $2.01 | $2.01 |
(Data provided by Zacks Investment Research)
Dividend History for Express Scripts Holding Company (NASDAQ:ESRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Express Scripts Holding Company (NASDAQ:ESRX)Insider Ownership Percentage: 0.68%
Institutional Ownership Percentage: 88.69%
Insider Trades by Quarter for Express Scripts Holding Company (NASDAQ:ESRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/11/2017 | Woodrow A Myers Jr | Director | Sell | 3,900 | $63.93 | $249,327.00 | |
| 9/8/2017 | Phyllis S Anderson | VP | Sell | 578 | $63.13 | $36,489.14 | |
| 8/23/2017 | Everett Neville | VP | Sell | 1,163 | $61.48 | $71,501.24 | |
| 5/19/2017 | Phyllis S Anderson | VP | Sell | 1,100 | $60.08 | $66,088.00 | |
| 3/1/2017 | Everett Neville | SVP | Sell | 2,352 | $70.16 | $165,016.32 | |
| 1/3/2017 | Everett Neville | VP | Sell | 1,123 | $69.41 | $77,947.43 | |
| 9/14/2016 | Woodrow A Myers Jr | Director | Sell | 12,036 | $70.40 | $847,334.40 | |
| 9/12/2016 | Christopher A Mcginnis | VP | Sell | 1,785 | $70.77 | $126,324.45 | |
| 5/10/2016 | Everett Neville | VP | Sell | 800 | $74.11 | $59,288.00 | |
| 4/29/2016 | Mahon Thomas P Mac | Director | Sell | 5,482 | $73.93 | $405,284.26 | |
| 3/10/2016 | Christopher A Mcginnis | VP | Sell | 579 | $68.56 | $39,696.24 | |
| 3/7/2016 | Phyllis S Anderson | VP | Sell | 614 | $71.14 | $43,679.96 | |
| 2/29/2016 | Everett Neville | VP | Sell | 4,323 | $71.00 | $306,933.00 | |
| 6/9/2015 | Gary Wimberly | VP | Sell | 1,644 | $87.14 | $143,258.16 | |
| 6/1/2015 | Gary Wimberly | VP | Sell | 46,069 | $86.15 | $3,968,844.35 | |
| 3/2/2015 | Glen D Stettin | VP | Sell | 2,674 | $84.39 | $225,658.86 | |
| 2/25/2015 | Glen D Stettin | VP | Sell | 27,603 | $87.55 | $2,416,642.65 | |
| 12/2/2014 | Keith J Ebling | VP | Sell | 10,000 | $84.25 | $842,500.00 | |
| 12/1/2014 | Steven B Miller | VP | Sell | 4,896 | $83.57 | $409,158.72 | |
| 11/28/2014 | Glen D Stettin | VP | Sell | 10,800 | $82.96 | $895,968.00 | |
| 11/17/2014 | John O Parker | Director | Sell | 25,822 | $78.75 | $2,033,482.50 | |
| 11/7/2014 | Maura C Breen | Director | Sell | 13,128 | $77.80 | $1,021,358.40 | |
| 9/5/2014 | Edward B Ignaczak | EVP | Sell | 9,886 | $75.28 | $744,218.08 | |
| 8/28/2014 | Seymour Sternberg | Director | Sell | 15,508 | $74.12 | $1,149,452.96 | |
| 8/25/2014 | Keith J Ebling | VP | Sell | 10,000 | $75.50 | $755,000.00 | |
| 8/5/2014 | Gary G Benanav | Director | Sell | 12,694 | $70.82 | $898,989.08 | |
| 8/5/2014 | Sara E Wade | VP | Sell | 20,000 | $70.44 | $1,408,800.00 | |
| 8/4/2014 | David A Norton | VP | Sell | 1,276 | $71.02 | $90,621.52 | |
| 8/1/2014 | Maura C Breen | Director | Sell | 12,694 | $69.94 | $887,818.36 | |
| 6/13/2014 | George Paz | CEO | Sell | 681,508 | $71.21 | $48,530,184.68 | |
| 3/11/2014 | Keith Ebling | VP | Sell | 25,721 | $78.69 | $2,023,985.49 | |
| 3/10/2014 | Patrick Mcnamee | COO | Sell | 68,425 | $78.28 | $5,356,309.00 | |
| 3/10/2014 | Steven Miller | VP | Sell | 12,664 | $77.96 | $987,285.44 | |
| 3/7/2014 | Keith Ebling | VP | Sell | 295,367 | $77.29 | $22,828,915.43 | |
| 1/9/2014 | Nicholas Lahowchic | Director | Sell | 7,650 | $72.00 | $550,800.00 | |
| 12/26/2013 | Nicholas Lahowchic | Director | Sell | 12,694 | $70.00 | $888,580.00 | |
| 11/5/2013 | Mahon Thomas Mac | Director | Sell | 10,251 | $63.20 | $647,863.20 | |
| 9/9/2013 | Maura C Breen | Director | Sell | 10,527 | $64.12 | $674,991.24 | |
| 9/4/2013 | Woodrow Myers, Jr. | Director | Sell | 7,128 | $64.66 | $460,896.48 | |
| 7/19/2013 | Nicholas Lahowchic | Director | Sell | 20,377 | $66.26 | $1,350,180.02 | |
| 6/11/2013 | Woodrow A Myers Jr | Director | Sell | 1,750 | $62.57 | $109,497.50 | |
| 5/28/2013 | Woodrow A Myers Jr | Director | Sell | 2,000 | $63.75 | $127,500.00 | |
| 5/15/2013 | Jeffrey Hall | CFO | Sell | 13,307 | $61.13 | $813,456.91 | |
| 5/8/2013 | Woodrow A Myers Jr | Director | Sell | 13,462 | $61.22 | $824,143.64 | |
| 5/1/2013 | Keith J Ebling | EVP | Sell | 59,494 | $59.58 | $3,544,652.52 | |
| 4/30/2013 | Patrick Mcnamee | COO | Sell | 271,972 | $59.65 | $16,223,129.80 | |
| 3/14/2013 | Mahon Thomas P Mac | Director | Buy | 5,000 | $59.58 | $297,900.00 | |
| 9/4/2012 | Jeffrey Hall | CFO | Sell | 75,000 | $62.81 | $4,710,750.00 | |
| 8/8/2012 | Edward B Ignaczak | EVP | Sell | 115,466 | $59.33 | $6,850,597.78 | |
(Data available from 1/1/2013 forward)
Headline Trends for Express Scripts Holding Company (NASDAQ:ESRX)
Latest Headlines for Express Scripts Holding Company (NASDAQ:ESRX)
| Source: |
|
| Date | Headline |
|---|
 | Company Spotlight: Express Scripts
www.nasdaq.com - October 17 at 7:10 PM |
 | Express Scripts Holding Company (ESRX) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 17 at 2:58 AM |
| Express Scripts Holding Company (ESRX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 16 at 2:56 PM |
 | Express Scripts to Acquire Medical Benefits Management Company - TheStreet.com
www.thestreet.com - October 15 at 10:40 PM |
 | Express Scripts to Acquire Medical Benefits Management Company
finance.yahoo.com - October 15 at 5:38 PM |
| FY2020 Earnings Estimate for Express Scripts Holding Company (ESRX) Issued By William Blair
www.americanbankingnews.com - October 13 at 4:20 PM |
| Express Scripts Holding Company (ESRX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 12 at 3:16 PM |
| William Blair Weighs in on Express Scripts Holding Company's Q1 2018 Earnings (ESRX)
www.americanbankingnews.com - October 12 at 11:52 AM |
 | Express Scripts (ESRX) to Acquire eviCore healthcare for $3.6B
www.streetinsider.com - October 11 at 7:56 PM |
| [$$] Amazon Could Partner With Express Scripts
finance.yahoo.com - October 11 at 7:56 PM |
| Express Scripts Holding Co. – Value Analysis (NASDAQ:ESRX) : October 11, 2017
finance.yahoo.com - October 11 at 7:56 PM |
| CareCore National, LLC -- Moody's places CareCore National's ratings on review for upgrade
finance.yahoo.com - October 11 at 7:56 PM |
 | Express Scripts: Another Potential Amazon Victim? - Benzinga
www.benzinga.com - October 11 at 2:15 AM |
 | Express Scripts Holding Company (ESRX) Buys eviCore Healthcare in $3.6B Deal - Investorplace.com
investorplace.com - October 11 at 2:15 AM |
| Express Scripts Holding Company -- Moody's affirms Express Scripts' Baa2 rating; stable outlook
finance.yahoo.com - October 10 at 9:12 PM |
| Express Scripts Inks Deal to Buy EviCore for $3.6 billion
www.thestreet.com - October 10 at 4:10 PM |
| Express Scripts To Acquire EviCore Healthcare For $3.6 Bln - Quick Facts
www.nasdaq.com - October 10 at 4:10 PM |
 | UPDATE: Express Scripts shares drop 2.5% on $3.6 bln eviCore acquisition
www.marketwatch.com - October 10 at 4:10 PM |
| Express Scripts To Buy eviCore For $3.6B As Value-Based Care Takes Hold
finance.yahoo.com - October 10 at 4:10 PM |
| [$$] Express Scripts to Buy eviCore for $3.6 Billion
finance.yahoo.com - October 10 at 4:10 PM |
| Express Scripts' Deal Helps Answer Amazon Threat
finance.yahoo.com - October 10 at 4:10 PM |
| Pharmacy benefit manager Express Scripts to buy eviCore for $3.6 bln
finance.yahoo.com - October 10 at 4:09 PM |
| Pharmacy benefit manager Express Scripts to buy eviCore for $3.6 billion
finance.yahoo.com - October 10 at 4:09 PM |
| Stocks Mixed but Gains in Walmart Push Dow Higher
finance.yahoo.com - October 10 at 4:09 PM |
| Express Scripts (ESRX) Dips on $3.6 Billion Deal to Buy EviCore Healthcare
finance.yahoo.com - October 10 at 4:09 PM |
 | Express Scripts buying eviCore for $3.6 billion
marketbeat.com - October 10 at 9:41 AM |
| Express Scripts Holding Company (ESRX) Earns "Underperform" Rating from Raymond James Financial, Inc.
www.americanbankingnews.com - October 9 at 8:54 AM |
| Express Scripts Holding Company (ESRX) Stock Rating Lowered by UBS AG
www.americanbankingnews.com - October 9 at 8:17 AM |
| Amazon Pharmacy Could Make Walgreens, CVS Sick
finance.yahoo.com - October 6 at 6:49 PM |
| Analyst: Amazon's Entry Into Pharmacy Is All But Certain At This Point
finance.yahoo.com - October 6 at 6:49 PM |
| Stock of Express Scripts (ESRX) Ranked a Sell - Investorplace.com
investorplace.com - October 5 at 9:26 AM |
| A New Normal? 870,000 Americans Used $50,000 Worth or More of Prescription Medicine in 2016
finance.yahoo.com - October 3 at 8:03 AM |
| Express Scripts Launches New Medicare Part D Saver Plan For 2018 - Quick Facts - Nasdaq
www.nasdaq.com - October 3 at 12:57 AM |
| When Should You Buy Express Scripts Holding Company (ESRX)?
finance.yahoo.com - October 2 at 7:55 PM |
| Brokerages Expect Express Scripts Holding Company (ESRX) to Announce $1.90 Earnings Per Share
www.americanbankingnews.com - October 2 at 4:18 PM |
| Is Express Scripts Holding (ESRX) a Great Stock for Value Investors?
www.nasdaq.com - September 27 at 6:29 PM |
| Novartis's $475,000 Price on Cancer Therapy Meets Resistance
finance.yahoo.com - September 22 at 8:23 AM |
| Express Scripts Holding Co. breached its 50 day moving average in a Bearish Manner : ESRX-US : September 19, 2017
finance.yahoo.com - September 19 at 6:23 PM |
| Royal Bank Of Canada Begins Coverage on Express Scripts Holding Company (ESRX)
www.americanbankingnews.com - September 19 at 7:38 AM |
| Research Analysts Issue Forecasts for Express Scripts Holding Company's Q1 2019 Earnings (ESRX)
www.americanbankingnews.com - September 18 at 8:00 AM |
| Why Express Scripts Holding Company (ESRX) Could Be A Buy
finance.yahoo.com - September 17 at 10:47 PM |
| Express Scripts Holding Company (ESRX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 17 at 1:20 PM |
| $25.67 Billion in Sales Expected for Express Scripts Holding Company (ESRX) This Quarter
www.americanbankingnews.com - September 15 at 5:40 AM |
| Express Scripts Holding Company (ESRX) VP Sells $36,489.14 in Stock
www.americanbankingnews.com - September 12 at 8:24 PM |
| Express Scripts Holding Company (ESRX) Director Sells $249,327.00 in Stock
www.americanbankingnews.com - September 12 at 7:52 PM |
| Express Scripts Offers Important Prescription Drug Information for Residents Impacted by Hurricane Irma
finance.yahoo.com - September 7 at 6:31 PM |
| Express Scripts Holding Company Announces Third Quarter 2017 Earnings Conference Call
finance.yahoo.com - September 5 at 8:04 PM |
| Express Scripts Holding Company (ESRX) Receives "Hold" Rating from Robert W. Baird
www.americanbankingnews.com - September 1 at 8:56 PM |
| Express Scripts Holding Co. breached its 50 day moving average in a Bullish Manner : ESRX-US : September 1, 2017
finance.yahoo.com - September 1 at 6:44 PM |
 | Loews Invests $21M in CVS; Tisch Buys GE - Barron's
www.barrons.com - August 30 at 7:42 PM |
Express Scripts Holding Company (ESRX) Chart for Wednesday, October, 18, 2017
